Clinical trials: Helicobacter
Helicobacter Pylori Infection
Long-term Follow-up of Interleukin-1B and H+,K+-ATPase mRNA Expression After Helicobacter Pylori Eradication
We will evaluate the long-term changes of gastric H+, K+-adenosine triphosphatase (H+, K+-ATPase) and Interleukin-1B mRNA expression according to Helicobacter pylori (H.pylori) infection and intestinal metaplasia and investigate…
- Trial name
- NCT04037904
- Where
- South Korea
- Volunteers
- 490 people
- Sponsor
- Seoul National University Bundang Hospital
Acute Coronary Syndrome
Relationship of Helicobacter Pylori Eradication Therapy and Long-term Outcome in Acute Coronary Syndrome
Objective: To investigate the relationship between Helicobacter pylori (Hp) infection and the prognosis of acute coronary syndrome (ACS) in a Chinese population and to explore the significance of Hp eradication therapy in…
- Trial name
- NCT02317445
- Volunteers
- 472 people
- Sponsor
- Capital Medical University
Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
This study is designed to demonstrate the non-inferiority and verify the safety of DWP14012-based triple therapy compared to DWC202301-based triple therapy as the first-line eradication therapy in patients who are positive for…
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects
- Trial name
- NCT06751121
- Testing
- DWP14012 40mg, DWC202301 30mg, Amoxicillin 1000mg
- Where
- South Korea
- Volunteers
- 461 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Stomach Ulcer
Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy
The purpose of this study is to evaluate the ulcer healing efficacy of rebamipide in comparison with omeprazole in Helicobacter pylori-positive gastric ulcer after eradication therapy.
- Trial name
- NCT00272467
- Testing
- Rebamipide, Omeprazole
- Where
- 7 sites in China, South Korea
- Volunteers
- 132 people
- Sponsor
- Korea Otsuka International Asia Arab
Ulcer Bleeding
Prevention of Recurrent Ulcer Bleeding in High-risk Aspirin Users Who Are Not Infected With Helicobacter Pylori
Low-dose aspirin is the mainstay of treatment for patients with coronary heart disease and stroke. However, low-dose aspirin increases the risk of ulcer bleeding.
- Trial name
- 3NANC (NCT01274767)
- Where
- China
- Volunteers
- 467 people
- Sponsor
- Chinese University of Hong Kong
Helicobacter Pylori Infection
Helicobacter Pylori and Lacidophilin Tablets in Combination With Vonorazan Dual Therapy
Our previous study included 119 Helicobacter pylori(H. pylori)-infected Chinese patients without previous eradication history who were randomized to low-or high-dose amoxicillin-vonoprazan regimens consisting of amoxicillin 1…
- Trial name
- NCT05749081
- Testing
- Lacidophilin tablets in combination with vonorazan dual therapy
- Where
- China
- Volunteers
- 324 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Helicobacter Pylori, Drug Resistance, Multiple
14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection
The goal of this clinical trial is to learn if the 14-day susceptibility-guided bismuth quadruple therapy works to treat multiple drug resistant Helicobacter pylori (H. pylori) in adults.
- Trial name
- BSUS-2 (NCT06687499)
- Testing
- Bismuth-based susceptibility-guided treatment
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- National Cheng-Kung University Hospital
Helicobacter Pylori
Vonoprazan Hp Dual or Triple Eradication Regimes
To evaluate the efficacy and safety of dual or triple regimes for Helicobacter Pylori eradication using Vonoprazan as the antiacid agent.
- Trial name
- NCT05345210
- Testing
- Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14), Vonoprazan Fumarate+Amoxycillin 14days (VA14), Vonoprazan Fumarate+Amoxycillin 7days (VA7)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Dyspepsia
Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Peptic ulcer disease is the most common gastrointestinal disease. Antibiotic resistant Helicobacter pylori is a major problem worldwide.
- Trial name
- NCT00285688
- Testing
- gastroscopic examination
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Dyspepsia
A Two Week Nitazoxanidebased Quadruple Regimen
Helicobacter pylori (H. pylori) infection is a global health problem as it is associated with peptic ulcers, chronic gastritis, duodenitis, and stomach cancer.
- Trial name
- NCT02621359
- Testing
- Nitazoxanide, Levofloxacin, Doxycyclin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Helicobacter Gastritis, Dyspepsia
Activation and Recruitment of GIL During Hp Infection
Helicobacter pylori is a major human pathogen that infects over half of the world population. Infection initiates a series of changes in the gastric mucosa, beginning with gastritis and leading in some patients to peptic ulcer…
- Trial name
- NCT00275886
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Gastric Cancer, Helicobacter Pylori Infection
A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
To observe the eradication rate of H. pylori infection, symptom improvement and the incidence of adverse effects in patients using a bismuth colloidal pectin granules quadruple therapy.
- Conditions
- Gastric Cancer, Helicobacter Pylori Infection, Bismuth
- Trial name
- NCT04660123
- Testing
- Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
- Where
- China
- Volunteers
- 959 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Helicobacter Pylori Infection
Clinical Utility of Upper Endoscopy in Diagnosis of Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is a gram-negative flagellated bacterium that inhabits the gastric environment of 60.3% of the world population, and its prevalence is particularly high in countries with inferior socioeconomic…
- Trial name
- NCT05787262
- Testing
- upper endoscopy
- Where
- Egypt
- Volunteers
- 345 people
- Sponsor
- Sohag University
Helicobacter Pylori Infection
Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection
This study aims to investigate eradication rate, drug compliance, and adverse events in patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth, metronidazole, and tetracycline for 14 days (TBMT) and…
- Trial name
- NCT04674774
- Testing
- Tegoprazan, Lansoprazole
- Where
- South Korea
- Volunteers
- 217 people
- Sponsor
- Incheon St.Mary's Hospital
HELICOBACTER PYLORI INFECTIONS, Hyperprolactinaemia
Impact of Helicobacter Pylori Infection on Prolactin Levels in Reproductive-Age Women to Determine Whether H. Pylori Infection is Associated with Elevated Prolactin Levels and Assess the Clinical Implications
The research is a cross-sectional observational study conducted at Assiut University Hospital. It will involve 75 women aged 18-45 with confirmed H. pylori infection. The study will measure serum prolactin levels and H.
- Trial name
- NCT06870773
- Volunteers
- 75 people
- Sponsor
- Assiut University
Therapeutic Duration, Helicobacter Pylori
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies. However, due to the increasing resistance rates to antibiotics, failures of H.
- Conditions
- Therapeutic Duration, Helicobacter Pylori, Antimicrobial Susceptibility Test, Eradication
- Trial name
- NCT02934048
- Testing
- 7-day triple regimen guided by AST, 10-day triple regimen guided by AST, 14-day triple regimen guided by AST
- Volunteers
- 700 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection, Obesity, Morbid
THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY
Laparoscopic sleeve gastrectomy is one of the most popular bariatric surgery in the world. The most important complication about this surgery that the leakage from the stapler line because of the inconvenient stapler choice..The…
- Trial name
- NCT03757650
- Testing
- Bismuth Subsalicylate
- Where
- Turkey (Türkiye)
- Volunteers
- 3 people
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
Peptic Ulcer
PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers
The aim of this study is to compare the efficacy of a proton pump inhibitor (lansoprazole) and a histamine-2 receptor antagonist (famotidine) in preventing recurrent ulcer bleeding in patients with a history of H.
- Trial name
- NCT01180179
- Testing
- Lansoprazole, Famotidine
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Chinese University of Hong Kong
Gastroesophageal Reflux Disease, Gastritis
Analysis of Biopsies From the Upper Gastrointestinal Tract
Multicenter study to correlate histological findings in the upper gastrointestinal tract with endoscopic and clinical data.
- Trial name
- histoGERD (NCT01576289)
- Testing
- Histological analysis
- Where
- Austria
- Volunteers
- 600 people
- Sponsor
- Medical University of Graz
Helicobacter Pylori Eradication Antibiotic
Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection
This study compared efficacy and safety of Ilaprazole based bismuth-containing quadruple regimen therapy including Ilaprazole 5mg, Bismuth Potassium Citrate 220mg, Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID…
- Trial name
- NCT02835560
- Testing
- Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy, Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
- Volunteers
- 100 people
- Sponsor
- Livzon Pharmaceutical Group Inc.